4 completed, 3 recruiting, 2 unknown, 2 withdrawn. 12 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 4, Recruiting 3, Unknown 2, Withdrawn 2, Terminated 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Myxofibrosarcoma: new trials by email Literature Review of Myxofibrosarcoma trials Research Report on Myxofibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2012-08-22 | 2017-11-30 |
Dermatofibrosarcoma (12) · Histiocytoma, Malignant Fibrous (11) · Sarcoma (10) · Leiomyosarcoma (9) · Liposarcoma (8) · Sarcoma, Synovial (8) · Neurofibrosarcoma (6) · Fibrosarcoma (4) · Hemangiosarcoma (4) · Bone Neoplasms (2) · Chondrosarcoma, Extraskeletal Myxoid (2) · Histiocytoma, Angiomatoid Fibrous (2) · Liposarcoma, Myxoid (2) · Nerve Sheath Neoplasms (2) · Osteosarcoma (2)
Neoplasms by Histologic Type (12) · Neoplasms, Connective Tissue (12) · Neoplasms, Connective and Soft Tissue (12) · Neoplasms, Fibrous Tissue (12) · Histiocytoma (11) · Neoplasms (11) · Neoplasms, Muscle Tissue (10) · Fibrosarcoma (8) · Neoplasms, Adipose Tissue (7) · Neoplasms, Nerve Tissue (6) · Nervous System Diseases (6) · Nervous System Neoplasms (6) · Neurofibroma (6) · Neuromuscular Diseases (6) · Peripheral Nervous System Diseases (6)
Doxorubicin (3) · pazopanib (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Docetaxel (2) · Gemcitabine (2) · Ifosfamide (2) · Dactinomycin (1) · Dexrazoxane (1) · Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · MLN 8237 (1) · Proton Therapy (1) · Radiation (1) · Radiation Dose Hypofractionation (1) · Radiotherapy (1)
National Cancer Institute (NCI) (3) · Brown University (2) · BioAtla, Inc. (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Memorial Sloan Kettering Cancer Center (1) · Oslo University Hospital (1) · St. Jude Children's Research Hospital (1) · Tracon Pharmaceuticals Inc. (1) · Washington University School of Medicine (1)
United States (10) · Canada (1) · Hong Kong (1) · Norway (1) · Poland (1) · Puerto Rico (1) · Taiwan (1) · United Kingdom (1)
Aaron R Weiss (1) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Charles Theuer, MD, PhD (1) · Don S Dizon, MD (1) · Edmund Bartlett, MD (1) · Galina G Lagos, MD (1) · Ivar Hompland, MD, PhD (1) · Jessica Gartrell, MD (1) · Kjetil Boye, MD, PhD (1) · Mark Dickson (1) · William D Tap (1)
PMID 27502708, PMID 32702309, PMID 32827353, PMID 34515544, PMID 34722269, PMID 37523624, PMID 38579194, PMID 42194972
U10CA180821 (2), U10CA031946 (1), U10CA098543 (1), U10CA180830 (1), U10CA180886 (1)